TY - JOUR T1 - <sup>68</sup>Ga-PSMA-PET/CT and bone scintigraphy imaging for staging of high-risk prostate cancer. JF - Journal of Nuclear Medicine JO - J Nucl Med SP - 757 LP - 757 VL - 58 IS - supplement 1 AU - Thabo Lengana AU - Moshe Modiselle AU - Ismaheel Lawal AU - Gill BOSHOMANE AU - Thomas Ebenhan AU - Mariza Vorster AU - Machaba Sathekge Y1 - 2017/05/01 UR - http://jnm.snmjournals.org/content/58/supplement_1/757.abstract N2 - 757Objectives: 68Ga-ligands targeting prostate-specific membrane antigen (PSMA) are rapidly emerging as a significant step forward in the management of prostate cancer, based on the fact that PSMA is a type II transmembrane protein with high expression in prostate carcinoma cells. We prospectively evaluated the use of 68Ga-PSMA-PET/CT in patients with prostate cancer and compared the results with those for 99mTc-MDP bone scintigraphy. Methods: Sixty-seven patients with biopsy-proven prostate cancer referred for standard-of-care bone scintigraphy were prospectively enrolled in this study. 68Ga-PSMA-PET/CT was performed after bone scintigraphy. Metastasis diagnosed on each of these techniques was compared against a final diagnosis based on contrast-enhanced CT, MRI, skeletal survey, clinical follow-up, and histological correlation.Results: The mean age was 67.5 years, their median PSA level was 97.5 ng/mL, and the mean Gleason score of the tumours was 8. A total of 94 bone lesions were interpreted as bone metastases in the 33 men on 68Ga-PSMA-PET/CT, compared to only 80 lesions in 18 men on 99mTc-MDP bone scintigraphy. The median standardized uptake values (SUV) in all malignant bone lesions was 11.07. 68Ga-PSMA-PET/CT showed significantly higher sensitivity and accuracy than bone scintigraphy (90.5% vs. 73.68%, and 97.0% vs. 86%) for the detection of skeletal lesions. For extraskeletal lesions, 68Ga-PSMA-PET/CT showed 83 unexpected lesions with a median standardized uptake values (SUV) of 9.9. Conclusion: 68Ga-PSMA-PET/CT is superior to 99mTc-MDP scintigraphy for evaluation of skeletal disease extent and may be useful in patients with high-risk prostate cancer and a negative or inconclusive bone scan. Further, 68Ga-PSMA-PET/CT detected extraskeletal disease that may change the management of these patients. Research Support: Own Funded ER -